News articles about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.9366932577158 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Agios Pharmaceuticals (AGIO) and The Competition Head-To-Head Analysis (americanbankingnews.com)
- Analyzing Agios Pharmaceuticals (AGIO) and The Competition (americanbankingnews.com)
- Agios Pharmaceuticals Inc (AGIO) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Analyzing Agios Pharmaceuticals (AGIO) & Its Competitors (americanbankingnews.com)
Agios Pharmaceuticals (NASDAQ:AGIO) traded up $3.99 during trading on Monday, hitting $58.12. 519,659 shares of the stock were exchanged, compared to its average volume of 505,566. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $72.73. The company has a market cap of $2,830.00, a P/E ratio of -9.27 and a beta of 1.83.
AGIO has been the topic of a number of research reports. Oppenheimer set a $83.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 17th. Royal Bank of Canada started coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price on the stock. BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. JPMorgan Chase & Co. restated a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Finally, SunTrust Banks restated a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $75.70.
In related news, Director Lewis Clayton Jr. Cantley sold 3,838 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the completion of the transaction, the director now directly owns 80,851 shares of the company’s stock, valued at approximately $4,800,123.87. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $60.79, for a total transaction of $130,455.34. Following the transaction, the insider now directly owns 8,410 shares of the company’s stock, valued at $511,243.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 127,746 shares of company stock valued at $8,733,196. 5.43% of the stock is owned by corporate insiders.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.